DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors. Source
No articles found.
Kitov Pharma is an innovative biopharmaceutical drug development company. Leveragi...
Kitov Pharma is an innovative biopharmaceutical...
BASi provides drug discovery and development services and analytical instruments t...
BASi provides drug discovery and development se...
Today's adults juggle caring for aging parents and children while working full-tim...
Today's adults juggle caring for aging parents ...
Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...
Founded in 1998, GW is a biopharmaceutical comp...
We are committed to advancing the treatment of eye conditions such as keratoconus ...
We are committed to advancing the treatment of ...
IVERIC bio is a gene therapy focused company developing innovative treatments for ...
IVERIC bio is a gene therapy focused company de...
We are a leading precision oncology company focused on helping conquer cancer glob...
We are a leading precision oncology company foc...
Join the National Investor Network and get the latest information with your interests in mind.